Trump is unlikely to end Medicare drug price talks — here's what that means for patients and pharma
Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper ...
Hosted on MSN1d
Overcoming Weight Loss Setbacks: A Middle-Aged Woman’s Guide to Lasting Fitness Success.
Weight loss setbacks are frustrating, but they don’t have to derail progress. As women, our bodies change over time, and ...
Let Medicare cover weight loss drugs to make America healthy
If Robert F. Kennedy Jr. and the Trump administration want to make America healthy again, they should let Medicare cover ...
Verywell Health4d
Does Berberine Aid Weight Loss? A Dietitian Explains
Impact on brown adipose tissue: Berberine may lower weight by increasing brown adipose tissue, a type of fat tissue that ...
ConsumerAffairs4d
Here are the health pros and cons of GLP-1RA weight loss drugs
New GLP-1RA weight loss drugs like Like Ozempic and Wegovy have become extremely popular in recent months but researchers ...
Stocktwits on MSN4d
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars
Shares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 weight-loss drugs, Zepbound and Mounjaro, missed estimates for the second ...
Novo Nordisk 'comfortable' with impact of Medicare price negotiations for GLP-1s: CEO
Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...
Novo Nordisk beats on Wegovy sales, expects slower 2025 growth
Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss ...
Lilly Needs a Plan to Spur Weight-Loss Drug Sales, Investors Say
Lilly Chief Financial Officer Lucas Montarce told Reuters last month the drugmaker is trying to balance its demand-generation activities with its ability to supply more patients. The company last year ...